RLAY insider disclosures
Explore public SEC filings by reporting investor and stock. Filings can appear after the activity they describe. Joint filing lines link to each reporting owner’s profile.
| Reporting investor | Security | Activity | Transaction / period | Filed | Reported amount | Source | Follow |
|---|---|---|---|---|---|---|---|
| Patel Sanjiv President and CEO · Director · Relay Therapeutics, Inc. | RLAY Relay Therapeutics, Inc. | SellFiling detailsSEC transaction code S Common Stock · Direct ownership · Reported balance after transaction: 423099 · SEC code covers open-market or private transactions · The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on October 30, 2025. · This transaction was executed in multiple trades at prices ranging from $15.89 to $16.72. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer or a security holder of the Issuer, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. | 2026-11-19 | 2026-11-20 | ≈ $777,498.26 48,202 shares/units | SEC 4 | Follow |
| Bergstrom Donald A President, R&D · Relay Therapeutics, Inc. | RLAY Relay Therapeutics, Inc. | SellFiling detailsSEC transaction code S Common Stock · Direct ownership · Reported balance after transaction: 386609 · SEC code covers open-market or private transactions · The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on October 30, 2025. · This transaction was executed in multiple trades at prices ranging from $16.30 to $16.99. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer or a security holder of the Issuer, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. · Includes 5,013 shares underlying restricted stock units. | 2026-11-18 | 2026-11-20 | ≈ $169,541.19 10,269 shares/units | SEC 4 | Follow |
| Catinazzo Thomas Chief Financial Officer · Relay Therapeutics, Inc. | RLAY Relay Therapeutics, Inc. | SellFiling detailsSEC transaction code S Common Stock · Direct ownership · Reported balance after transaction: 70948 · SEC code covers open-market or private transactions · The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on October 30, 2025. · This transaction was executed in multiple trades at prices ranging from $16.30 to $17.12. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer or a security holder of the Issuer, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. · Includes 3,269 shares underlying restricted stock units. | 2026-11-18 | 2026-11-20 | ≈ $540,157.67 32,717 shares/units | SEC 4 | Follow |
Form 4 buy and sell codes cover open-market or private transactions. Form 13F shows quarterly reported holdings. Position changes can have causes other than trading. Disclosures are delayed and provided for research.